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Background: Chromosomally encoded AmpC β-lactamases may be acquired by transmissible plasmids which
consequently can disseminate into bacteria lacking or poorly expressing a chromosomal blaAmpC gene. Nowadays,
these plasmid-mediated AmpC β-lactamases are found in different bacterial species, namely Enterobacteriaceae,
which typically do not express these types of β-lactamase such as Klebsiella spp. or Escherichia coli. This study was
performed to characterize two E. coli isolates collected in two different Portuguese hospitals, both carrying a novel
CMY-2-type β-lactamase-encoding gene.
Findings: Both isolates, INSRA1169 and INSRA3413, and their respective transformants, were non-susceptible to
amoxicillin, amoxicillin plus clavulanic acid, cephalothin, cefoxitin, ceftazidime and cefotaxime, but susceptible to
cefepime and imipenem, and presented evidence of synergy between cloxacilin and cefoxitin and/or ceftazidime.
The genetic characterization of both isolates revealed the presence of blaCMY-46 and blaCMY-50 genes, respectively,
and the following three resistance-encoding regions: a Citrobacter freundii chromosome-type structure encompassing a
blc-sugE-blaCMY-2-type-ampR platform; a sul1-type class 1 integron with two antibiotic resistance gene cassettes (dfrA1 and
aadA1); and a truncated mercury resistance operon.
Conclusions: This study describes two new blaCMY-2-type genes in E. coli isolates, located within a C. freundii-derived
fragment, which may suggest their mobilization through mobile genetic elements. The presence of the three different
resistance regions in these isolates, with diverse genetic determinants of resistance and mobile elements, may further
contribute to the emergence and spread of these genes, both at a chromosomal or/and plasmid level.
Keywords: β-lactamase, Resistance regions, Genetic environment, Escherichia coliBackground
AmpC β-lactamases, along with Class A β-lactamases, are
a major group of clinically important enzymes [1,2]. They
belong to class C according to the Ambler classification
and to group 1 following the functional classification of
Bush-Jacoby [3,4], whose prevalence is increasing world-
wide [1]; these β-lactamases are associated with infections
caused by pathogenic Gram-negative bacteria, particularly
Escherichia coli and Klebsiella pneumoniae. The identifica-
tion of isolates containing plasmid-mediated AmpC-β-
lactamase (PMAβ) is epidemiologically and clinically rele-
vant due to the limitations of treatment options [5].* Correspondence: manuela.canica@insa.min-saude.pt
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and cephamycins (cefoxitin and cefotetan) and, at a low
level, oxyiminocephalosporins (ceftazidime, cefotaxime, and
ceftriaxone) and aztreonam: they are not inhibited by β-
lactamase inhibitors such as clavulanic acid [1]. AmpC-
producing isolates are susceptible to carbapenems and to
zwitterionic cephalosporins (cefepime and cefpirome).
In this study, we performed the phenotypic and molecu-
lar characterization of two new CMY-2-types (designated
CMY-46 and CMY-50), both encoded by probably chromo-
somal inducible ampC genes, produced by two clinical E.
coli isolates. The genetic environment of blaCMY-46 and
blaCMY-50 was also investigated.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Bacterial isolate collection
Two clinical E. coli strains (INSRA1169 and INSRA3413)
were isolated, in 1999, from urine samples of two patients
of 77 years and 7 months old, in two different hospitals in
Portugal. E. coli DH5α (pBK-CMY-2) strain was used as
control for antimicrobial susceptibility tests.
Antimicrobial susceptibility tests
Minimal inhibitory concentrations were determined by a
microdilution method according to guidelines of the
French Society of Microbiology (SFM 2013, http://www.
sfm-microbiologie.org/) against seven β-lactams, alone or
in combination with clavulanic acid, and against ciprofloxa-
cin, gentamicin and trimethoprim. Isolates non-susceptible
to one third-generation cephalosporin, cefoxitin and/or
exhibiting synergy with boronic acid and/or cloxacillin,
were considered as presumptive AmpC producers. Imipi-
nem and clavulanic acid were used in order to identify in-
duction effect of AmpC [1,6]. Disks of inducing agents
(imipenem 10 μg and amoxicillin plus clavulanic acid 25 +
10 μg) and disks of cephalosporins (cefotaxime 30 μg and
ceftazidime 30 μg) were placed on Mueller–Hinton agar
plates, 20 mm apart. Positive induction was demonstrated
by the antagonism effect surrounding the cephalosporin
disks adjacent to the inducers.
Isoelectric point determination
β-Lactamases were characterized by isoelectric focusing
of ultrasonicated bacterial extracts with the control
strains expressing pI 5.2, 5.6, 7.6, 9.0, 9.2, as previously
described [7].
Molecular characterization of ampC and ESBL-encoding
genes
The presence of acquired ampC (blaCMY, blaMOX, blaFOX,
blaLAT, blaACT, blaMIR, blaDHA, blaMOR, blaACC) and
blaESBL genes (blaTEM, blaSHV, blaOXA-1-type, blaCTX-M) was
investigated by multiplex PCR assays with primers and
conditions as described elsewhere [7-10], and those from
Table 1. Controls were included in all assays.
Gene transfer experiments
Transferability of the blaCMY genes was attempted by both
broth mating-out assays and electroporation. Conjugation
experiments were performed at 37°C, using recipient
strains E. coli C600 RifR, StrR and E. coli J53 NaN3
R,
according to the antibiotic susceptibilities of the clinical
isolates used as donor. Transconjugants were selected on
MacConkey agar plates containing 250 μg/ml of rifampi-
cin, 160 μg/ml of streptomycin or 160 μg/ml of sodium
azide plus 10 μg/ml of cefoxitin. Plasmid DNA was
extracted from clinical strains, using the Wizard Plus
Midipreps DNA Purification kit (Promega), and used totransform electrocompetent E. coli DH5α ΔampC by elec-
troporation, as previously described [7]. Transformants
were selected on Luria broth medium containing 10 μg/
ml of cefoxitin.
Cloning experiments
The blaCMY-2, blaCMY-46 and blaCMY-50 genes were amp-
lified with iProofTM High-Fidelity DNA Polymerase
(Bio-Rad, Hercules, CA), using primers from Table 1.
Amplicons (1169 bp) were ligated in the SmaI site of the
phagemid pBK-CMV (Stratagene) downstream of its in-
ducible lacZ promoter and transformed into electrocom-
petent E. coli DH5α ΔampC cells. A gene Pulser II
apparatus (Bio-Rad, Hercules, CA) was used for standard
electroporation techniques, as previously described [7].
Recombinant bacteria were selected on LB agar plates
containing 10 μg/ml of cefoxitin.
Genetic background characterization
The presence of class 1 integrons was determined in both
isolates through PCR amplification of the integrase-specific
intI1 gene with the same specific primers and conditions as
reported previously [11] (Table 1). PCR-mapping and se-
quencing of the genetic environment of blaCMY-46 and
blaCMY-50 was performed using primers targeting genes
known for promoting antibiotic resistance and integrons
(Table 1). Sequence alignments and generation of resistance
cassette contigs were performed using Bionumerics (Ap-
plied Maths). Gene identity was confirmed at the NCBI
website (http://www.ncbi.nlm.nih.gov/).
Findings
The two clinical E. coli isolates INSRA1169 and
INSRA3413 were resistant to amoxicillin, amoxicillin plus
clavulanic acid, cephalothin, cefoxitin, ceftazidime, cefo-
taxime, gentamicin and trimethoprim, but susceptible to
cefepime and imipenem (Table 2). INSRA1169 was also
nonsusceptible to ciprofloxacin. Synergy between cloxacil-
lin and cefoxitin plus cefotaxime and boronic acid, along
with the absence of synergy between extended-spectrum
cephalosporins and clavulanic acid, suggest that the resist-
ance to extended-spectrum cephalosporins was mediated
by the overproduction of AmpC β-lactamases. The resist-
ance phenotype was not transferable, neither in conjuga-
tion assays with E. coli C600 as a recipient, or in
transformation assays by electroporation of plasmid-DNA
preparations into E. coli DH5α. This might suggest a
chromosomal location of AmpC-encoding genes.
Transformants, obtained after cloning of DNA ampli-
cons of INSRA1169 and INSRA3413 in pBK-CMV plas-
mid vector (Figure 1a), showed a resistance phenotype
similar to that of clinical isolates. However, they were
susceptible to ciprofloxacin, gentamicin and trimetho-
prim, like the control strain E. coli DH5α (pBK-CMY-2)
Table 1 Primers, drawn in this study, used for PCR amplification and sequencing of PMAβ genes and for PCR mapping
of blaCMY-46 and blaCMY-50
Gene (s) Primer Sequence (5’→ 3’) PCR product
(bp) / MethodaForward Reverse
blaCMY-G2 TTACGGAACTGATTTCATG TCGTCAGTTATTGCAGC 1169 / PCR + Seq.
orf513 GCCAGGTCTTGAGTATCGTC CATGTAATTGAGTCAGCGTATC 363 / PCR + Seq.
fdrB - fdrD CTCAGTTGACCACCACGAAC GAATGCCAATAGCCGTTACGAC 920 / PCR + Seq.
fdrB - ampR CTCAGTTGACCACCACGAAC CACCAGTCAGAATGTTCACGCA 1140 / PCR + Seq.
ampR - blaCMY-G2 TGCGTGAACATTCTGACTGGTG TTTCTCCTGAACGTGGCTGGC 1660 / PCR + Seq.
blaCMY-G2 - sugE TGGCCAGAACTGACAGGCAAA ATGTCCTGGATCGTTTTATTA 1751 / PCR + Seq.
merA- urf2 TTCCCCTACCTGACGATGG TGTTGCAGGCAGGAATAGC 1214/ PCR + Seq.
merR - merA TCTTTCTCCCCTTGCAGCG CACCTTGTCGAACAGCCCA Variable / PCR + Seq.
merA CGTCCAATCTGCCATAGTG GTAGGGGAACAACTGGTCG Seq.
merD CCTTCGAGGCGGGTATC CCGATACCCGCCTCGAAG Seq.
aMethod used for screening and/or identification of genes: M-PCR, Multiplex-PCR; Seq, sequencing; PCR + Seq, PCR and sequencing.
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produced β-lactamases exhibiting an alkaline isoelectric
point (pI 9.2) compatible with AmpC-type β-lactamases.
Indeed, PCR revealed the absence of blaESBL genes plus
the presence of chromosomal E. coli ampC-type gene;
the sequence of cloned DNA fragments identified two
new CMY-2-like genes, which were not related to
chromosome-mediated E. coli AmpC gene. The chromo-
somal location of such genes has only been observed in
Salmonella spp. and Proteus mirabilis isolates [12-14].
The deduced amino acid sequences confirmed that
the new genes encoding the β-lactamases CMY-46 (in
INSRA1169) and CMY-50 (in INSRA3413), which were
new variants of CMY-2, differed by 9 and 13 amino acid
substitutions, respectively (Table 3). Two of these muta-
tions (Q193K plus P208A for CMY-46 and N194S plus
D198N for CMY-50) are in the Ω loop (between amino
acids 178 and 226), which interacts by hydrogen bond-
ing with helix H-2 close to the active Ser64. Substitu-
tions in this region have been linked to the extension of
the hydrolysis spectrum [15]. However, CMY-46 andTable 2 MICs of antibiotics for CMY-46- and CMY-50-producin
E. coli strain MIC (μg/ml)b
AMX AMCc CF CAZ CC
DH5α ΔampC 8 8 8 0.25 0.1
DH5α (pBK-CMY-2) >2048 >2048 1024 32 16
INSRA1169 (CMY-46 + TEM-1) >2048 >2048 1024 16 4
DH5α (pBK-CMY-46) >2048 >2048 1024 32 4
INSRA3413 (CMY-50) >2048 >2048 1024 16 8
DH5α (pBK-CMY-50) >2048 >2048 1024 16 8
aE. coli EcDH5α (pBK-CMY-2) was control strain; E. coli DH5α (pBK-CMY-46) and E. co
CMY-46 and TEM-1 enzymes) and E. coli INSRA3413 (harboring CMY-50 enzyme), re
bAMX, amoxicillin; AMC, amoxicillin-clavulanic acid; CF, cephalothin; CAZ, ceftazidim
cefoxitin; IMP, imipenem; CIP, ciprofloxacin; GEN, gentamicin and TMP, trimethoprim
cClavulanic acid, at fixed concentration of 2 μg/ml.CMY-50 β-lactamases did not confer resistance to cefe-
pime and conferred low level of resistance to ceftazi-
dime and cefotaxime, which suggests that, in contrast to
extended-spectrum AmpCs, they have moderate or no
extended-spectrum activity (Table 2) [15-18].
The study of sequences surrounding blaCMY-46 and
blaCMY-50 revealed the presence of the blc gene (encoding
an outer membrane lipoprotein) and the sugE gene (encod-
ing a small MDR protein responsible for resistance to qua-
ternary ammonium compounds) downstream of their open
reading frames (Figure 1a). Upstream, an ampR gene encod-
ing the usual transcriptional regulator of ampC genes was
observed in an opposite direction of transcription (Figure 1a).
The presence of an intact ampC-ampR segment in both
new blaCMY genetic regions implied that the production of
CMY-46 and CMY-50 is inducible, which was corroborated
by the used phenotypic induction method. This ampC-
ampR region was identical to the sequence flanking the
blaAmpC gene in the C. freundii chromosome [6], except for
AmpRCMY-46 (that had 4 amino acid substitutions), but none
were located in the helix-turn-helix region or in otherg E. coli isolates and E. coli transformants and recipientsa
AZc CTX FEP FOX IMP CIP GEN TMP
25 0.06 0.03 4 0.25 ≤0.125 ≤0.125 ≤0.25
8 0.25 64 0.5 ≤0.125 1 ≤0.25
4 0.032 64 2 4 >128 >128
8 0.25 64 0.5 ≤0.125 2 ≤0.25
4 0.25 64 2 ≤0.125 64 64
4 0.25 64 0.5 ≤0.125 0.5 ≤0.25
li DH5α (pBK-CMY-50) were transformants of E. coli INSRA1169 (harboring
spectively; E. coli EcDH5α was the recipient strain.
e; CCAZ, ceftazidime-clavulanic acid; CTX, cefotaxime; FEP, cefepime; FOX,
.
urf2 merE merD merA
truncated mer operon, 852bpC
intl1 dfrA1 aadA1 qacE 1 sul1
Class 1 integron, 3,191bpB
A
E. coli: genetic environment of blaCMY-type genes, 2954bp
blaCMY-typeampR sugEblc
C. freundii :chromosomal region (JH414884), 34,816bp
574,378bp 609,195bp588,947bp 592,040bp
Figure 1 Schematic representation of the same three structures found within clinical isolates expressing blaCMY-46 and blaCMY-50. The
directions of transcription of the corresponding genes are depicted by arrows. A: sequence, including the genetic environment of blaCMY-type
genes, compared with C. freundii chromosomal region (GenBank JH414884); B: class 1 integron, with attI1 site (grey circle) and the two attc
regions (open circles); C: truncated mercury resistance operon.
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regions of our blaCMY-2-type and ampR genes harbored no
sequence element associated with increased strength of the
promoter [20,21]. In addition, the frdD, frdC, and frdB genes
that are usually adjacent to ampC-ampR in the C. freundii
chromosome were not identified in the sequences flanking
blaCMY-46 or blaCMY-50.
Class 1 integrons, also detected in INSRA1169 and
INSRA3413 (Figure 1b), comprised the integrase-encoding
gene intI1, two gene cassettes, aacA1 and dfrA1, and
qacEΔ1 plus sul1, which were probably responsible for the
observed resistances to trimethoprim and aminoglycosides.Table 3 Comparison of amino acid substitutions of two new C
PMAβ Amino acid at position no.a
3 3 4 1 1 1 1 1 1 1 1
2 5 9 0 0 2 2 3 4 6 9
2 5 4 6 3 3 4 0
CMY-2 V Q A Q R D R H T K T
CMY-46 T S T R A
CMY-50 I E R S E T R Q
aNumbering according to Bauernfeind et al., 1996 [19].We also found a truncated mercury resistance operon
(Figure 1c), which was previously reported as belonging to
a “kan region” that included a kanamycin resistance gene
[22]. This finding is of concern since mercury resistance
may help to promote antibiotic resistance through indirect
selection [23].
In summary, this study describes two new blaCMY-2-type
genes located within a C. freundii-derived fragment.
Considering that CMY-type β-lactamases, detected in E.
coli, are derived from the C. freundii chromosomal
AmpC [1] and that chromosome-derived genes are usu-
ally mobilized by MGE [24,25], the presence of threeMY-type β-lactamases
pI Accession
Number
1 1 1 2 2 2 2 2 3
9 9 9 0 3 4 5 6 4
3 4 8 8 6 2 3 1 8
Q N D P A H A R V 9.0 X91840
K A V R 9.2 FN556186
S N E C A 9.2 FN645444
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MGE in this study, suggests the dynamics of bacteria in the
transference of antibiotic resistance. In addition, they might
also trigger the future emergence and spread of these resist-
ant determinants both at a chromosomal or/and plasmid
level.
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